PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29501569-10 2018 CONCLUSIONS: Bach2 may play a suppressive role in B cells from SLE, and BCR-ABL may inhibit the nuclear translocation of Bach2 via serine phosphorylation through the PI3K pathway. Serine 131-137 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 72-79 29665256-5 2018 We further demonstrated that BCR-ABL enhances the prolyl isomerase activity of Pin 1 by decreasing the phosphorylated level of Pin 1 at Ser 71 and interacting with DAPK1. Serine 136-139 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 29-36 21445688-5 2012 By using antibody which specifically recognizes phosphorylated serines (S807/811) in the c-Abl tyrosine kinase binding C-domain of human pRb, we provide evidence for the cell cycle-dependent changes in pRb-like proteins in root meristems cells of Vicia faba. Serine 63-70 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 89-94 24891505-5 2014 We show that this significant affinity difference is due to the substitution of arginine 161 and serine 187 in Abl to leucine 207 and threonine 233 in Arg, respectively. Serine 97-103 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 111-114 28378189-5 2017 Serine and tyrosine phosphorylation of galectin-3 by c-Abl, CKI, and GSK-3beta could regulate its localization and associated signal transduction. Serine 0-6 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 53-58 25944899-4 2015 c-Abl and HIPK2 synergized in activating p53 on apoptotic promoters in a reporter assay, and c-Abl was required for endogenous HIPK2 accumulation and phosphorylation of p53 at Ser(46) in response to DNA damage by gamma- and UV radiation. Serine 176-179 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-5 25944899-4 2015 c-Abl and HIPK2 synergized in activating p53 on apoptotic promoters in a reporter assay, and c-Abl was required for endogenous HIPK2 accumulation and phosphorylation of p53 at Ser(46) in response to DNA damage by gamma- and UV radiation. Serine 176-179 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 93-98 25944899-8 2015 These data demonstrate a new mechanism for the induction of DNA damage-induced apoptosis by c-Abl and illustrate network interactions between serine/threonine and tyrosine kinases that dictate cell fate. Serine 142-148 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 92-97 24480037-0 2014 Serine and proline-rich ligands enriched via phage-display technology show preferential binding to BCR/ABL expressing cells. Serine 0-6 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 99-106 24480037-7 2014 These peptides contained either multiple proline residues or serine/threonine-proline pairs and showed a confirmed binding preference for BCR/ABL+ fibroblasts. Serine 61-67 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 138-145 24263804-0 2014 PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis. Serine 20-26 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 59-66 24263804-3 2014 We have investigated the importance of STAT5 serine phosphorylation for BCR-ABL-induced leukemogenesis. Serine 45-51 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 72-79 23318434-5 2013 On one hand, Abl indirectly enhanced phosphorylation of Myc on Ser 62 and Thr 58, its association with Pin1 and p300 and its acetylation by p300. Serine 63-66 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 13-16 22334513-3 2012 Previous studies have established that ataxia telangiectasia mutated (ATM) activates nuclear Abl by phosphorylating serine 465 (S465) in the kinase domain in response to ionizing radiation (IR). Serine 116-122 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 93-96 21209314-6 2011 We demonstrate that phosphorylation at serine 292 controls RIN1-mediated inhibition of cell migration by modulating the activation of Abl kinases. Serine 39-45 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 134-137 21900237-7 2011 The Abi1 phosphorylated on serine 216 displayed greatly reduced tyrosine phosphorylation in the hematopoietic cells transformed by Bcr-Abl. Serine 27-33 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 131-138 21455220-4 2011 Met ensures cell survival through a new path in which c-Abl and p38-MAPK are employed to elicit p53 phosphorylation on Ser(392) and Mdm2 upregulation. Serine 119-122 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 54-59 17431132-4 2007 Enhanced ATM kinase-dependent phosphorylation of Nbs1 on serine 343 (S343) in response to genotoxic treatment was detected in leukemia cells expressing BCR/ABL and other FTKs in comparison to normal counterparts stimulated with IL-3, GM-CSF, and SCF. Serine 57-63 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 152-159 19643477-4 2010 Those effects are at least partly conditional upon the enhanced nuclear accumulation of p145 c-ABL through events encompassing post-translational modifications of p145 c-ABL (Thr(735) phosphorylation) precluding its nuclear export and of 14-3-3 sigma (Ser(186) phosphorylation by c-Jun N-terminal kinase [JNK]) promoting p145 c-ABL nuclear re-import. Serine 252-255 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 93-98 19643477-4 2010 Those effects are at least partly conditional upon the enhanced nuclear accumulation of p145 c-ABL through events encompassing post-translational modifications of p145 c-ABL (Thr(735) phosphorylation) precluding its nuclear export and of 14-3-3 sigma (Ser(186) phosphorylation by c-Jun N-terminal kinase [JNK]) promoting p145 c-ABL nuclear re-import. Serine 252-255 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 168-173 19442657-2 2009 Here we show that the interaction between hMSH5 and c-Abl confers ionizing radiation (IR)-induced apoptotic response by promoting c-Abl activation and p73 accumulation, and these effects are greatly enhanced in cells expressing hMSH5(P29S) (i.e. the hMSH5 variant possessing a proline to serine change within the N-terminal (Px)(5) dipeptide repeat). Serine 288-294 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 52-57 19261608-7 2009 The Abl kinase inhibitors and depletion of Bcr-Abl induced the expression of PHLPP1 and PHLPP2, which dephosphorylated Ser-473 on Akt1, -2, and -3, resulting in inhibited proliferation of CML cells. Serine 119-122 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 43-50 18161990-2 2008 The interaction of c-Abl with the Abl interactor protein Abi2 is shown to be negatively regulated by phosphorylation of serines 637 and 638. Serine 120-127 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 19-24 18161990-2 2008 The interaction of c-Abl with the Abl interactor protein Abi2 is shown to be negatively regulated by phosphorylation of serines 637 and 638. Serine 120-127 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 21-24 18161990-5 2008 Mutation of serines 637-639 to alanine (3A) or aspartate (3D) results in an increased tyrosine kinase activity of c-Abl 3D, and a slight reduction of the activity of the 3A mutant, as compared to wild-type (WT) c-Abl. Serine 12-19 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 114-119 18161990-5 2008 Mutation of serines 637-639 to alanine (3A) or aspartate (3D) results in an increased tyrosine kinase activity of c-Abl 3D, and a slight reduction of the activity of the 3A mutant, as compared to wild-type (WT) c-Abl. Serine 12-19 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 211-216 19643477-4 2010 Those effects are at least partly conditional upon the enhanced nuclear accumulation of p145 c-ABL through events encompassing post-translational modifications of p145 c-ABL (Thr(735) phosphorylation) precluding its nuclear export and of 14-3-3 sigma (Ser(186) phosphorylation by c-Jun N-terminal kinase [JNK]) promoting p145 c-ABL nuclear re-import. Serine 252-255 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 168-173 19261608-10 2009 Thus, Bcr-Abl represses the expression of PHLPP1 and PHLPP2 and continuously activates Akt1, -2, and -3 via phosphorylation on Ser-473, resulting in the proliferation of CML cells. Serine 127-130 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 6-13 19220809-2 2009 In particular, constitutive tyrosine kinase (TK) activity of p210 BCR-ABL blocks c-Jun N-terminal kinase (JNK) phosphorylation leading to 14-3-3 sigma phosphorylation at a critical residue (Ser(186)) for c-ABL binding in response to DNA damage. Serine 190-193 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 66-73 18759402-8 2008 The RDF design allows inclusion of extended binding determinants to maximize recognition by the cognate kinase, which has now permitted the construction of chemosensors for a variety of representative Ser/Thr (PKC alpha, PKC betaIota, PKC delta, Pim2, Akt1, MK2, and PKA) as well as receptor (IRK) and nonreceptor (Src, Abl) Tyr kinases with greatly enhanced selectivity. Serine 201-204 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 320-323 17475908-3 2007 In fact, high levels of p210-BCR/ABL are required for enhanced hnRNP-E2 expression, which depends on phosphorylation of hnRNP-E2 serines 173, 189, and 272 and threonine 213 by the BCR/ABL-activated MAPK(ERK1/2). Serine 129-136 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 24-36 17475908-3 2007 In fact, high levels of p210-BCR/ABL are required for enhanced hnRNP-E2 expression, which depends on phosphorylation of hnRNP-E2 serines 173, 189, and 272 and threonine 213 by the BCR/ABL-activated MAPK(ERK1/2). Serine 129-136 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 33-36 17475908-4 2007 Serine/threonine to alanine substitution abolishes hnRNP-E2 phosphorylation and markedly decreases its stability in BCR/ABL-expressing myeloid precursors. Serine 0-6 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 116-123 16702947-3 2006 As part of this mechanism ATM itself, and the ATM-activated protein tyrosine kinase, c-Abl, inhibit Hdm2 function through phosphorylation of serine 395 and tyrosine 394 (Y394), respectively. Serine 141-147 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 85-90 17318191-1 2007 Self-renewal of Bcr-Abl(+) chronic myeloid leukemia (CML) cells is sustained by a nuclear activated serine/threonine-(S/T) unphosphorylated beta-catenin. Serine 100-106 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 16-23 11376433-6 2001 Using these antibodies, we established/confirmed the in vivo phosphorylation of Ser-354, Tyr-328, and Tyr-360 in Bcr and Bcr-Abl proteins. Serine 80-83 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 121-128 12476302-8 2002 In the case of Bcr(64-413), serine 354 is required for the formation of the unique Bcr structure that binds to the Abl SH2 domain. Serine 28-34 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 115-118 12167702-4 2002 In contrast to the serine 32/34 phosphorylation that triggers ubiquitination and degradation of IkappaBalpha, c-Abl-mediated phosphorylation at tyrosine 305 is associated with an increase of the IkappaBalpha protein stability. Serine 19-25 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 110-115 9168116-7 1997 Ectopic expression of a functional ATM kinase domain corrects this defect, as it phosphorylates the c-Abl tyrosine kinase in vitro at Ser 465, leading to the activation of c-Abl. Serine 134-137 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 100-105 9168116-7 1997 Ectopic expression of a functional ATM kinase domain corrects this defect, as it phosphorylates the c-Abl tyrosine kinase in vitro at Ser 465, leading to the activation of c-Abl. Serine 134-137 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 172-177 8912843-4 1996 Similarly, a Bcr peptide phosphorylated on Ser-354 blocked the c-Abl and Bcr-Abl kinases in vitro, whereas the same peptide phosphorylated on Tyr-360 was not inhibitory. Serine 43-46 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 63-68 8912843-4 1996 Similarly, a Bcr peptide phosphorylated on Ser-354 blocked the c-Abl and Bcr-Abl kinases in vitro, whereas the same peptide phosphorylated on Tyr-360 was not inhibitory. Serine 43-46 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 73-80 8626527-10 1996 In contrast, Ser-807/811 phosphorylation is required to disrupt c-Abl binding. Serine 13-16 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 64-69 8637883-6 1996 p140/c-Abl is quantitatively the minor population, is heavily phosphorylated at both serine and tyrosine residues, and is active in autophosphorylation reactions. Serine 85-91 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 5-10